5,049 results on '"Rivastigmine"'
Search Results
2. Toward a Computationally-Informed, Personalized Treatment for Hallucinations
- Author
-
National Institute of Mental Health (NIMH)
- Published
- 2024
3. Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine (PRECISER)
- Author
-
ZonMw: The Netherlands Organisation for Health Research and Development, St. Antonius Hospital, Tergooi Hospital, and Iris Sommer, Professor
- Published
- 2024
4. Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium (RIVA-AP)
- Author
-
American Academy of Clinical Toxicology and Kevin Baumgartner, Assistant Professor of Emergency Medicine
- Published
- 2024
5. Rivastigmine for Antimuscarinic Delirium (RIVA-AM)
- Author
-
American Academy of Clinical Toxicology and Kevin Baumgartner, Assistant Professor of Emergency Medicine
- Published
- 2024
6. Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h)
- Published
- 2024
7. Drug Response of Iranian Alzheimer’s Patients to Rivastigmine Concerning Their Genotype for VDR rs11568820 and MTHFR C677T Variants: A Pharmacogenetic and Association Study.
- Author
-
Rizi, Zahra Salimian, Shams, Leila, Rad, Fatemeh Rezaei, and Zamani, Mahdi
- Abstract
Alzheimer’s disease is a neurodegenerative disorder with polygenic etiology. Genetic risk variants for Alzheimer’s disease differ among populations. Thus, discovering them in each population is clinically important. A total of 118 patients and 97 controls for VDR rs11568820 and 88 patients and 100 healthy controls for MTHFR C677T polymorphism were genotyped to evaluate the association of these polymorphisms with late-onset Alzheimer’s disease in the Iranian population, along with their impacts on the response to Rivastigmine treatment. The VDR C allele was significantly associated with Alzheimer’s disease and provided protection against it (P = 0.003, RR = 1.14, 95% CI 1.04–1.24), while the T allele increased susceptibility (P = 0.003, RR = 1.93, 95% CI 1.23–3.02). These results were also considerable upon excluding the effect of APOE ε4 allele. The Prevalence-corrected Positive Predictive Value was 1.71% for the VDR CC genotype and 4% for the VDR CT genotype, indicating lower and almost twofold higher chances of developing Alzheimer’s disease, respectively. No significant correlation was observed between MTHFR C677T and Alzheimer’s disease. Based on our pharmacogenetic study, MTHFR T allele carriers lacking APOE ε4 allele showed a better response to Rivastigmine treatment after a 2-year follow-up. Moreover, patients with VDR CC genotype displayed milder Alzheimer’s disease, particularly when coincided with the APOE ε4 allele. The VDR rs11568820 polymorphism affects both Alzheimer’s disease risk and the response to Rivastigmine in Iranian patients. Also, MTHFR C677T polymorphism may play a role in the response to Rivastigmine, through a pathway that needs to be elucidated in future studies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Donepezil as a safe alternative treatment after maculo‐papular eruption related to rivastigmine in Lewy body disease: a case report and pharmacovigilance data.
- Author
-
Chouchana, Margot, Pinel, Sylvine, Colboc, Hester, Soria, Angele, Buard, Geraldine, Delage, Clément, Bloch, Vanessa, and Lilamand, Matthieu
- Subjects
- *
RIVASTIGMINE , *DONEPEZIL , *ACNEIFORM eruptions , *NICOTINIC acetylcholine receptors - Abstract
This article discusses a case report and pharmacovigilance data regarding the use of donepezil as an alternative treatment for a patient with Lewy body disease who experienced a maculo-papular eruption after taking rivastigmine. The patient initially experienced a localized rash at the patch application site, but the eruption spread after switching to oral capsules. The adverse reaction was likely due to rivastigmine itself. The article suggests that donepezil may be a safe alternative treatment for patients who experience cutaneous adverse reactions to rivastigmine. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
9. New 1,2,4-oxadiazole derivatives as potential multifunctional agents for the treatment of Alzheimer's disease: design, synthesis, and biological evaluation.
- Author
-
Ayoup, Mohammed Salah, Ghanem, Mariam, Abdel-Hamid, Hamida, Abu-Serie, Marwa M., Masoud, Aliaa, Ghareeb, Doaa A., Hawsawi, Mohammed B., Sonousi, Amr, and Kassab, Asmaa E.
- Subjects
- *
ALZHEIMER'S disease , *METHYLENE blue , *MOLECULAR docking , *CHEMICAL synthesis , *RIVASTIGMINE - Abstract
A series of new 1,2,4-oxadiazole-based derivatives were synthesized and evaluated for their anti-AD potential. The results revealed that eleven compounds (1b, 2a-c, 3b, 4a-c, and 5a-c) exhibited excellent inhibitory potential against AChE, with IC50 values ranging from 0.00098 to 0.07920 µM. Their potency was 1.55 to 125.47 times higher than that of donepezil (IC50 = 0.12297 µM). In contrast, the newly synthesized oxadiazole derivatives with IC50 values in the range of 16.64–70.82 µM exhibited less selectivity towards BuChE when compared to rivastigmine (IC50 = 5.88 µM). Moreover, oxadiazole derivative 2c (IC50 = 463.85 µM) was more potent antioxidant than quercetin (IC50 = 491.23 µM). Compounds 3b (IC50 = 536.83 µM) and 3c (IC50 = 582.44 µM) exhibited comparable antioxidant activity to that of quercetin. Oxadiazole derivatives 3b (IC50 = 140.02 µM) and 4c (IC50 = 117.43 µM) showed prominent MAO-B inhibitory potential. They were more potent than biperiden (IC50 = 237.59 µM). Compounds 1a, 1b, 3a, 3c, and 4b exhibited remarkable MAO-A inhibitory potential, with IC50 values ranging from 47.25 to 129.7 µM. Their potency was 1.1 to 3.03 times higher than that of methylene blue (IC50 = 143.6 µM). Most of the synthesized oxadiazole derivatives provided significant protection against induced HRBCs lysis, revealing the nontoxic effect of the synthesized compounds, thus making them safe drug candidates. The results unveiled oxadiazole derivatives 2b, 2c, 3b, 4a, 4c, and 5a as multitarget anti-AD agents. The high AChE inhibitory potential can be computationally explained by the synthesized oxadiazole derivatives' significant interactions with the AChE active site. Compound 2b showed good physicochemical properties. All these data suggest that 2b could be considered as a promising candidate for future development. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Cardiovascular Effects of Acetylcholinesterase Inhibitors
- Author
-
Stojiljković, Miloš P., Škrbić, Ranko, Maksimović, Žana M., Dhalla, Naranjan S., Series Editor, Bolli, Roberto, Editorial Board Member, Goyal, Ramesh, Editorial Board Member, Kartha, Chandrasekharan, Editorial Board Member, Kirshenbaum, Lorrie, Editorial Board Member, Makino, Naoki, Editorial Board Member, Mehta, Jawahar L. L., Editorial Board Member, Ostadal, Bohuslav, Editorial Board Member, Pierce, Grant N., Editorial Board Member, Slezak, Jan, Editorial Board Member, Varro, Andras, Editorial Board Member, Werdan, Karl, Editorial Board Member, Weglicki, William B., Editorial Board Member, Djuric, Dragan M., editor, and Agrawal, Devendra K., editor
- Published
- 2024
- Full Text
- View/download PDF
11. Major Neurocognitive Disorders Due to Parkinson’s Disease
- Author
-
Rajaram Manoharan, Senthil Vel Rajan, Walia, Jessy, Bozman, Mack, Tampi, Rajesh R., editor, and Tampi, Deena J., editor
- Published
- 2024
- Full Text
- View/download PDF
12. Major Neurocognitive Disorders Due to Alzheimer’s Disease
- Author
-
Joshi, Pallavi, Patel, Nisha, Gopalakrishna, Ganesh, Tampi, Rajesh R., editor, and Tampi, Deena J., editor
- Published
- 2024
- Full Text
- View/download PDF
13. Systematic Evaluation of the Efficacy and Safety of Rivastigmine in Combination with Memantine for Mild to Moderate Alzheimer’s Disease Based on MCMC Algorithm
- Author
-
Yue, Hui, Bao, Hong-rui, Cui, Yan-yin, Hou, Wen-xin, Wen, Hong-juan, Ceccarelli, Marco, Series Editor, Agrawal, Sunil K., Advisory Editor, Corves, Burkhard, Advisory Editor, Glazunov, Victor, Advisory Editor, Hernández, Alfonso, Advisory Editor, Huang, Tian, Advisory Editor, Jauregui Correa, Juan Carlos, Advisory Editor, Takeda, Yukio, Advisory Editor, and Li, Shaofan, editor
- Published
- 2024
- Full Text
- View/download PDF
14. Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease
- Author
-
National Institute on Aging (NIA) and F. Rainer von Coelln, MD, Assistant Professor
- Published
- 2023
15. CHIEF PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease) (CHIEF PD)
- Author
-
Royal United Hospitals Bath NHS Foundation Trust
- Published
- 2023
16. Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)
- Author
-
SocraTec R&D GmbH and SocraMetrics GmbH
- Published
- 2023
17. Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)
- Published
- 2023
18. Directed Evolution and Immobilization of Lactobacillus brevis Alcohol Dehydrogenase for Chemo‐Enzymatic Synthesis of Rivastigmine.
- Author
-
Su, Guorong, Ran, Lu, Liu, Chang, Qin, Zhaoyang, Teng, Huailong, and Wu, Shuke
- Subjects
- *
ALCOHOL dehydrogenase , *LACTOBACILLUS brevis , *RIVASTIGMINE , *ALZHEIMER'S disease , *HEAVY metals , *GLUCOSE oxidase - Abstract
Rivastigmine is one of the several pharmaceuticals widely prescribed for the treatment of Alzheimer's disease. However, its practical synthesis still faces many issues, such as the involvement of toxic metals and harsh reaction conditions. Herein, we report a chemo‐enzymatic synthesis of Rivastigmine. The key chiral intermediate was synthesized by an engineered alcohol dehydrogenase from Lactobacillus brevis (LbADH). A semi‐rational approach was employed to improve its catalytic activity and thermal stability. Several LbADH variants were obtained with a remarkable increase in activity and melting temperature. Exploration of the substrate scope of these variants demonstrated improved activities toward various ketones, especially acetophenone analogs. To further recycle and reuse the biocatalyst, one LbADH variant and glucose dehydrogenase were co‐immobilized on nanoparticles. By integrating enzymatic and chemical steps, Rivastigmine was successfully synthesized with an overall yield of 66 %. This study offers an efficient chemo‐enzymatic route for Rivastigmine and provides several efficient LbADH variants with a broad range of potential applications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. The Influence of an Acute Administration of Cannabidiol or Rivastigmine, Alone and in Combination, on Scopolamine-Provoked Memory Impairment in the Passive Avoidance Test in Mice.
- Author
-
Kruk-Slomka, Marta, Slomka, Tomasz, and Biala, Grazyna
- Subjects
- *
MEMORY disorders , *RIVASTIGMINE , *MICE , *CANNABIDIOL , *CHOLINERGIC mechanisms , *CHOLINERGIC receptors - Abstract
Memory is one of the most important abilities of our brain. The process of memory and learning is necessary for the proper existence of humans in the surrounding environment. However, sometimes there are unfavourable changes in the functioning of the brain and memory deficits occur, which may be associated with various diseases. Disturbances in the cholinergic system lead to abnormalities in memory functioning and are an essential part of clinical symptoms of many neurodegenerative diseases. However, their treatment is difficult and still unsatisfactory; thus, it is necessary to search for new drugs and their targets, being an alternative method of mono- or polypharmacotherapy. One of the possible strategies for the modulation of memory-related cognitive disorders is connected with the endocannabinoid system (ECS). The aim of the present study was to determine for the first time the effect of administration of natural cannabinoid compound (cannabidiol, CBD) and rivastigmine alone and in combination on the memory disorders connected with cholinergic dysfunctions in mice, provoked by using an antagonist of muscarinic cholinergic receptor—scopolamine. To assess and understand the memory-related effects in animals, we used the passive avoidance (PA) test, commonly used to examine the different stages of memory. An acute administration of CBD (1 mg/kg) or rivastigmine (0.5 mg/kg) significantly affected changes in scopolamine-induced disturbances in three different memory stages (acquisition, consolidation, and retrieval). Interestingly, co-administration of CBD (1 mg/kg) and rivastigmine (0.5 mg/kg) also attenuated memory impairment provoked by scopolamine (1 mg/kg) injection in the PA test in mice, but at a much greater extent than administered alone. The combination therapy of these two compounds, CBD and rivastigmine, appears to be more beneficial than substances administered alone in reducing scopolamine-induced cognitive impairment. This polytherapy seems to be favourable in the pharmacotherapy of various cognitive disorders, especially those in which cholinergic pathways are implicated. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Rivastigmine for treatment-refractory posttraumatic stress disorder: a systematic review.
- Author
-
Maguire, Paul A., Bastiampillai, Tarun, Allison, Stephen, Wilkes, Fiona, and Looi, Jeffrey C. L.
- Subjects
- *
RIVASTIGMINE , *POST-traumatic stress disorder , *COMBINATION drug therapy , *MEDICAL information storage & retrieval systems , *SELF-evaluation , *CINAHL database , *TREATMENT effectiveness , *SYSTEMATIC reviews , *MEDLINE , *DRUG efficacy , *ONLINE information services , *DRUG resistance , *EVALUATION - Abstract
We conducted a systematic review evaluating the efficacy of rivastigmine augmentation for treatmentrefractory posttraumatic stress disorder (PTSD). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. The databases Ovid MEDLINE, PubMed, CINAHL, and EMBASE were searched using key words: 'rivastigmine' OR 'Exelon' OR 'rivastigmine augmentation' OR 'Exelon augmentation' AND 'posttraumatic stress disorder*' OR 'post-traumatic stress disorder*' OR 'PTSD' OR 'combat disorder*' OR 'post-traumatic symptoms'. The asterisk specified plural forms of the relevant word. Four papers were identified, comprising one double-blind randomised controlled trial, one non-controlled open trial, one case series (presenting three case studies), and one paper with two case studies. The randomised controlled trial found no statistically significant difference in efficacy, using the PTSD CheckList'Military Version as the relevant outcomes measure, between the active add-on rivastigmine interventions and placebo or treatment as usual. The open trial, although reporting relatively positive outcomes, had a weak study design and lacked reporting of key information, including participant sex and age and pre-rivastigmine PTSD measures. The assessment of efficacy was based on participants' reporting of subjective benefits, and clinician-rating using a Clinical Global Impression, rather than established PTSD assessments scales. Although the five case studies reported improvement in PTSD symptoms, there were confounding factors and limitations in clinical and demographic data, warranting caution regarding attributed benefits. There is a lack of methodologically robust evidence supporting the efficacy of add-on rivastigmine for the treatment of refractory PTSD. Additional research may help in further evaluating its possible clinical efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. The effectiveness of preoperative delirium prevention in intermediate to high‐risk older surgical patients: A systematic review.
- Author
-
Lay, Nicholas, Foley, Pieternella, and Allen, Jacqueline
- Subjects
- *
ELDER care , *RIVASTIGMINE , *SURGERY , *PATIENTS , *DISEASE duration , *SEDATIVES , *CINAHL database , *PREOPERATIVE care , *TREATMENT effectiveness , *SEVERITY of illness index , *MELATONIN , *HALOPERIDOL , *MEDLINE , *ORTHOPEDIC surgery , *SURGICAL complications , *DELIRIUM , *GERIATRIC assessment , *TRANSCUTANEOUS electrical nerve stimulation , *ACUPUNCTURE points , *COGNITIVE therapy , *METHYLPREDNISOLONE , *LENGTH of stay in hospitals , *NERVE block , *DISEASE incidence , *EVALUATION , *MIDDLE age , *OLD age ,PREVENTION of surgical complications ,DIGESTIVE organ surgery - Abstract
Background: Few reviews have addressed delirium prevention among intermediate to high‐risk older surgical patients. Aims: To map preoperative delirium prevention interventions for older surgical patients at intermediate to high risk of developing delirium, assess outcomes and identify gaps in knowledge. Design: Systematic narrative review of randomised controlled trials reported following the PRISMA checklist. Methods: A systematic search was conducted of the literature published from 1990 to October 2022 in Medline, CINAHL and Ageline and of the grey literature in Google Scholar. Randomised controlled trials were retrieved that assessed the effectiveness of preoperative delirium prevention interventions for older surgical patients at intermediate to high risk of delirium. Data were extracted using a data extraction tool, and results were tabulated. Studies were assessed for bias using the Cochrane Collaboration Risk of Bias tool. Results: Twenty‐one studies met the selection criteria including N = 5096 participants. Two studies tested cognitive training, two studies tested fascia iliaca compartment block and one study assessed femoral nerve block. Ten studies tested prophylactic medications including methylprednisolone. Five studies investigated geriatric assessment and management. One study assessed transcutaneous electrical acupoint stimulation. In the two studies testing fascia iliaca compartment block, there was a reduction in postoperative delirium for orthopaedic patients. Methylprednisolone reduced postoperative delirium in orthopaedic patients and in those undergoing gastrointestinal surgery. Results of all other interventions on the occurrence of postoperative delirium and additional outcomes including the severity and duration of delirium were inconclusive. Conclusions: Despite the promising results for fascia iliaca compartment block and methylprednisolone, there is limited knowledge regarding evidence‐based delirium prevention interventions. Most studies had small sample sizes indicating that the current evidence is exploratory. There is an urgent need for the funding and conduct of trials to test preventative interventions for older surgical patients at intermediate to high risk of developing delirium. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Trends of use and characterisation of anti-dementia drugs users: a large multinational-network population-based study.
- Author
-
Reyes, Carlen, Newby, Danielle, Raventós, Berta, Verhamme, Katia, Mosseveld, Mees, Prieto-Alhambra, Daniel, Burn, Edward, and Duarte-Salles, Talita
- Subjects
- *
ATTENTION-deficit hyperactivity disorder , *REPORTING of diseases , *DESCRIPTIVE statistics , *LONGITUDINAL method , *MEDICATION therapy management , *DEMENTIA , *CONFIDENCE intervals , *DEMENTIA patients , *DISEASE incidence - Abstract
Background An updated time-trend analysis of anti-dementia drugs (ADDs) is lacking. The aim of this study is to assess the incident rate (IR) of ADD in individuals with dementia using real-world data. Setting Primary care data (country/database) from the UK/CPRD-GOLD (2007–20), Spain/SIDIAP (2010–20) and the Netherlands/IPCI (2008–20), standardised to a common data model. Methods Cohort study. Participants: dementia patients ≥40 years old with ≥1 year of previous data. Follow-up: until the end of the study period, transfer out of the catchment area, death or incident prescription of rivastigmine, galantamine, donepezil or memantine. Other variables: age/sex, type of dementia, comorbidities. Statistics: overall and yearly age/sex IR, with 95% confidence interval, per 100,000 person-years (IR per 105 PY (95%CI)). Results We identified a total of (incident anti-dementia users/dementia patients) 41,024/110,642 in UK/CPRD-GOLD, 51,667/134,927 in Spain/SIDIAP and 2,088/17,559 in the Netherlands/IPCI. In the UK, IR (per 105 PY (95%CI)) of ADD decreased from 2007 (30,829 (28,891–32,862)) to 2010 (17,793 (17,083–18,524)), then increased up to 2019 (31,601 (30,483 to 32,749)) and decrease in 2020 (24,067 (23,021–25,148)). In Spain, IR (per 105 PY (95%CI)) of ADD decreased by 72% from 2010 (51,003 (49,199–52,855)) to 2020 (14,571 (14,109–15,043)). In the Netherlands, IR (per 105 PY (95%CI)) of ADD decreased by 77% from 2009 (21,151 (14,967–29,031)) to 2020 (4763 (4176–5409)). Subjects aged ≥65–79 years and men (in the UK and the Netherlands) initiated more frequently an ADD. Conclusions Treatment of dementia remains highly heterogeneous. Further consensus in the pharmacological management of patients living with dementia is urgently needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. RETRACTED: QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer's therapeutics.
- Author
-
Arora, Deepshi, Bhatt, Shailendra, Kumar, Manish, Verma, Ravinder, Taneja, Yugam, Kausha, Nikita, Tiwari, Abhishek, Tiwari, Varsha, Alexiou, Athanasios, Albogami, Sarah, Alotaibi, Saqer S., Mittal, Vineet, Singla, Rajeev K., Kaushik, Deepak, and Batiha, Gaber El-Saber
- Abstract
Alzheimer's disease (AD) is a neurodegenerative disease that affects a wide range of populations and is the primary cause of death in various countries. The treatment of AD is still restricted to oral conventional medicines that act only superficially. Fabrication of intranasal solid lipid nanoparticulate system for the uptake of therapeutic agents will act as a convincing approach with limited off-site toxicity and increased pharmacological activity. The objective of this study was to formulate, optimize, and evaluate the efficiency of rivastigmine tartrate (RT)-loaded intranasal solid lipid nanoparticles (SLNs) employing the solvent-evaporation diffusion method. To optimize the formulation parameters, the central composite design (CCD) was used. Lipid concentration (X1) and surfactant concentration (X2) were considered to be independent variables, while particle size (Y1), percentage entrapment efficiency (Y2), and percentage drug release (Y3) were considered as responses. The solid lipid was glyceryl monostearate, while the surfactant was polysorbate 80. The optimized formulation has a particle size of 110.2 nm, % entrapment efficiency of 82.56%, and % drug release of 94.86%. The incompatibility of drug excipients was established by differential scanning calorimetry (DSC) and Fourier-transform infrared spectroscopy (FTIR). Nasal histopathology tests on sheep mucosa revealed that the developed SLNs were safe to utilize for intranasal delivery with no toxicity. Ex vivo permeation investigations revealed that the flux and diffusion coefficients for RT solid lipid nanoparticles and RT solution were 3.378 g/cm² /h and 0.310
-3 cm² /h, respectively. Stability studies demonstrated that the developed SLNs were stable when stored under various storage conditions. The viability and vitality of adopting a lipid particle delivery system for improved bioavailability via the intranasal route were also established in the in vivo pharmacokinetic investigations. According to the histopathological and pharmacokinetic investigations, the developed formulations were safe, non-lethal, efficient, and robust. These results suggest the potentiality provided by rivastigmine tartrate-loaded solid lipid nanoparticles for nasal delivery. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
24. Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer's-like Tauopathy Mouse Model.
- Author
-
Zadrozny, Maciej, Drapich, Patrycja, Gasiorowska-Bien, Anna, Niewiadomski, Wiktor, Harrington, Charles R., Wischik, Claude M., Riedel, Gernot, and Niewiadomska, Grazyna
- Subjects
- *
TAUOPATHIES , *RIVASTIGMINE , *TAU proteins , *INTERNEURONS , *LABORATORY mice , *ALZHEIMER'S disease , *SEPTUM (Brain) - Abstract
Basal forebrain cholinergic dysfunction, most likely linked with tau protein aggregation, is a characteristic feature of Alzheimer's disease (AD). Recent evidence suggests that tau protein is a putative target for the treatment of dementia, and the tau aggregation inhibitor, hydromethylthionine mesylate (HMTM), has emerged as a potential disease-modifying treatment. However, its efficacy was diminished in patients already receiving approved acetylcholinesterase inhibitors. In this study, we ask whether this negative interaction can also be mimicked in experimental tau models of AD and whether the underlying mechanism can be understood. From a previous age profiling study, 6-month-old line 1 (L1) tau transgenic mice were characterized by a severe reduction in several cholinergic markers. We therefore assessed whether long-term pre-exposure with the acetylcholinesterase inhibitor rivastigmine alone and in conjunction with the tau aggregation inhibitor HMTM can reverse cholinergic deficits in L1. Rivastigmine and HMTM, and combinations of the two compounds were administered orally for 11 weeks to both L1 and wild-type mice. The brains were sectioned with a focus on the basal forebrain, motor cortex and hippocampus. Immunohistochemical staining and quantification of choline acetyltransferase (ChAT), tyrosine kinase A (TrkA)-positive neurons and relative optical intensity (ROI) for vesicular acetylcholine transporter (VAChT), and acetylcholinesterase (AChE) reactivity confirmed reversal of the diminished cholinergic phenotype of interneurons (nucleus accumbens, striatum) and projection neurons (medial septum, nucleus basalis magnocellularis) by HMTM, to a greater extent than by rivastigmine alone in L1 mice. Combined administration did not yield additivity but, in most proxies, led to antagonistic effects in which rivastigmine decreased the benefits shown with HMTM alone. Local markers (VAChT and AChE) in target structures of the basal forebrain, motor cortex and hippocampal CA3 seemed to be normalized by HMTM, but not by rivastigmine or the combination of both drugs. HMTM, which was developed as a tau aggregation inhibitor, strongly decreased the tau load in L1 mice, however, not in combination with rivastigmine. Taken together, these data confirm a cholinergic phenotype in L1 tau transgenic mice that resembles the deficits observed in AD patients. This phenotype is reversible by HMTM, but at the same time appears to be subject to a homeostatic regulation induced by chronic pre-treatment with an acetylcholinesterase inhibitor, which interferes with the efficacy of HMTM. The strongest phenotypic reversal coincided with a normalization of the tau load in the cortex and hippocampus of L1, suggesting that tau accumulation underpins the loss of cholinergic markers in the basal forebrain and its projection targets. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy (RIVA-PSP)
- Published
- 2023
26. Alzheimer's disease - a review of medicinal substances and their derivatives
- Author
-
Marika Więcek, Dorota G. Piotrowska, Michał Kołodziejczyk, and Iwona E. Głowacka
- Subjects
alzheimer's disease ,memantine ,rivastigmine ,cholinesterase inhibitors ,donepezil ,galantamine ,multifunctional ligands ,Pharmacy and materia medica ,RS1-441 - Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder. Although the first case of Alzheimer’s disease was recorded over a century ago, the etiology of the disease remains unknown. There are several hypotheses regarding the process of neurodegeneration, however, it is impossible to provide a specific cause of Alzheimer’s disease in humans, due to the lack of in vivo models. Only a few specific changes in the body occurring in the course of this disease have been described so far, and no effective drugs have been developed to stop its progression. The effect of the currently used drugs is limited only to improving the cognitive functions and general patients’ well-being. Four medicinal substances have been approved for the treatment of Alzheimer's disease so far, namely, donepezil, rivastigmine, galantamine, and memantine. In this article, a brief description of marketed drugs used for the treatment of Alzheimer's disease is presented as well as selected substances in phase III clinical trials. Moreover, a strategy of multifunctional ligands along with a description of the activity of selected compounds containing in their structure a moiety of one of the drugs used in the treatment of Alzheimer’s disease, namely, donepezil, rivastigmine, or galantamine, is presented in the paper. Selected compounds synthesized over the last five years are described. Taking into account the multifactorial nature of Alzheimer's disease, the multifunctional ligands strategy directed at more than one biological target is used by many research groups. A large group of multi-target ligands is based on derivatives containing in their structure a moiety of selected acetylcholinesterase inhibitors. These moieties are combined with various types of compounds with known biological activity. As a result, derivatives with multi-target effects are obtained, mainly cholinesterase inhibitory properties and inhibition of the β-amyloid aggregation process, as well as antioxidant and neuroprotective effects.
- Published
- 2024
- Full Text
- View/download PDF
27. Are there links between Alzheimer’s disease and ADHD? The efficacy of acetylcholinesterase inhibitors and NMDA receptor antagonists in controlling ADHD symptoms: a systematic review
- Author
-
Ramin Abdi Dezfouli, Sara Akbariforoud, and Ensieh Esmaeilidezfouli
- Subjects
ADHD ,Alzheimer’s ,Donepezil ,Galantamine ,Memantine ,Rivastigmine ,Psychiatry ,RC435-571 - Abstract
Abstract Background To assess the effectiveness, safety, and tolerability of anti-Alzheimer agents (memantine, galantamine, rivastigmine, and donepezil) in controlling ADHD symptoms in children, adolescents, and adults. Methods Following the PRISMA guideline, clinical trials assessing the potency of anti-Alzheimer medications in managing ADHD symptoms were imported from PubMed, Web of Science, and Scopus (until February 2023). Screening stages were conducted by two independent researchers. Two independent researchers also extracted data from clinical trials reporting the outcomes as the reduction in scores of ADHD questionnaires. The risk of bias within the included studies was assessed using the Cochrane Collaboration tool, while the certainty of outcomes was evaluated based on the GRADE criteria. Results Of the initial 1597 studies, 11 studies were included. No studies were available for rivastigmine, and only a single study was conducted for galantamine. The results of the other two medications had a slight inconsistency. While both memantine and donepezil were reported to be effective in several studies, they were reported to be ineffective in some other studies. Side effects were mostly reduced appetite and headache. The tolerability of memantine, donepezil, and galantamine was all convincing. Conclusions While galantamine did not demonstrate a promising efficacy in ADHD, memantine and donepezil showed effectiveness. However, future studies are needed to confirm their efficacy in ADHD since there was some inconsistency.
- Published
- 2024
- Full Text
- View/download PDF
28. Efficacy and safety of chinese herbal medicines combined with chemical drugs for alzheimer's disease: A systematic review and meta-analysis
- Author
-
Li Xu, Wen-Jun Chen, Cai-Jun Tian, Yan Zhang, Yan Ma, Tian-Hao Li, Hong-Jie Liu, and Zhe Zhang
- Subjects
alzheimer's disease ,chinese herbal medicine ,donepezil ,memantine ,meta-analysis ,randomized controlled trials ,rivastigmine ,Medicine (General) ,R5-920 - Abstract
Objective: To evaluate the efficacy and safety of Chinese herbal medicines (CHMs) combined with chemical drugs for the treatment of Alzheimer's disease (AD). Materials and Methods: Databases were searched to retrieve randomized controlled trials (RCTs) of CHMs combined with tacrine, galantamine, rivastigmine, donepezil, or memantine, following strict inclusion and exclusion criteria. Only research papers published in English, Chinese, and Japanese were considered. The primary outcome was the mini-mental state examination (MMSE) score and the secondary outcomes were AD assessment scale cognitive subscale (ADAS-Cog) score and safety evaluation. Meta-analysis was carried out using RevMan 5.3 and subgroup analysis was conducted to identify the sources of heterogeneity. Results: A total of 15 RCTs with 1386 participants were included in this study. Only donepezil was used in the retrieved literature. Meta-analyses showed that the combination of CHMs with donepezil led to significant improvement in the MMSE score (Z = 9.45; P < 0.00001; weighted mean difference [WMD] =2.68, 95% confidence interval [CI]: 2.12–3.24) and a significant decrease in the ADAS-Cog score (Z = 5.53; P < 0.00001; WMD = −3.79; 95% CI: −5.13–−2.44). Safety evaluation demonstrated that these combination treatments relieved adverse events such as insomnia (risk ratio [RR] =0.20, 95% CI: 0.06–0.68; P = 0.01) and hive (RR = 0.10; 95% CI: 0.01–0.73; P = 0.02). Conclusions: The combination of CHMs with a chemical drug like donepezil led to significant improvements in patient cognition as well as a better safety profile when compared to the application of a chemical drug alone.
- Published
- 2024
- Full Text
- View/download PDF
29. Dual engine-driven bionic microneedles for early intervention and prolonged treatment of Alzheimer's disease.
- Author
-
Zhang, Minmin, Yang, Beibei, Ren, Tao, Wang, Xuewen, Chen, Hangping, Lu, Chao, Wu, Chuanbin, Pan, Xin, and Peng, Tingting
- Subjects
- *
ALZHEIMER'S disease , *BIONICS , *RECOGNITION (Psychology) , *ALZHEIMER'S patients , *DUAL-fuel engines , *DRUG bioavailability , *MEMORY disorders , *DRUG delivery devices - Abstract
The microneedle (MN) delivery system presents an attractive administration route for patients with Alzheimer's disease (AD). However, the passive drug delivery mode and low drug loading of MNs often result in unsatisfactory therapeutic efficiency. To address these dilemmas, we developed dual engine-drive bionic MNs for robust AD treatment. Specifically, free rivastigmine (RVT) and RVT particles were co-loaded within the MNs to construct the valve and chambers of the guava, respectively, which can serve as an active engine to promote drug permeation by generating capillary force. K 2 CO 3 and citric acid were introduced as a pneumatic engine into the MNs to promote the permeation of free RVT into deeper skin layers for early intervention in AD. Further, the RVT particles served as a drug depot to provide continuous drug release for prolonged AD treatment. Compared with free RVT-loaded MNs, the dual engine-driven bionic MNs showed an increase in drug loading, cumulative transdermal permeability, and normalized bioavailability of approximately 40%, 22%, and 49%, respectively. Pharmacodynamic studies further confirmed that the dual engine-driven bionic MNs were most effective in restoring memory and recognition functions in mice with short-term memory dysfunction. Therefore, the dual engine-driven bionic MNs hold great promise for highly efficient AD treatment. [Display omitted] • Bionic MNs driven with dual pneumatic and capillary forces significantly enhanced the drug loading and bioavailability of rivastigmine. • Bionic MNs with biphasic drug release behavior provided early intervention and prolonged treatment of Alzheimer's disease. • Bionic MNs effectively restored the memory and recognition functions of mice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Are there links between Alzheimer's disease and ADHD? The efficacy of acetylcholinesterase inhibitors and NMDA receptor antagonists in controlling ADHD symptoms: a systematic review.
- Author
-
Abdi Dezfouli, Ramin, Akbariforoud, Sara, and Esmaeilidezfouli, Ensieh
- Subjects
- *
ALZHEIMER'S disease , *METHYL aspartate receptors , *ACETYLCHOLINESTERASE inhibitors , *CLINICAL trial registries , *ATTENTION-deficit hyperactivity disorder , *ACETYLCHOLINESTERASE - Abstract
Background: To assess the effectiveness, safety, and tolerability of anti-Alzheimer agents (memantine, galantamine, rivastigmine, and donepezil) in controlling ADHD symptoms in children, adolescents, and adults. Methods: Following the PRISMA guideline, clinical trials assessing the potency of anti-Alzheimer medications in managing ADHD symptoms were imported from PubMed, Web of Science, and Scopus (until February 2023). Screening stages were conducted by two independent researchers. Two independent researchers also extracted data from clinical trials reporting the outcomes as the reduction in scores of ADHD questionnaires. The risk of bias within the included studies was assessed using the Cochrane Collaboration tool, while the certainty of outcomes was evaluated based on the GRADE criteria. Results: Of the initial 1597 studies, 11 studies were included. No studies were available for rivastigmine, and only a single study was conducted for galantamine. The results of the other two medications had a slight inconsistency. While both memantine and donepezil were reported to be effective in several studies, they were reported to be ineffective in some other studies. Side effects were mostly reduced appetite and headache. The tolerability of memantine, donepezil, and galantamine was all convincing. Conclusions: While galantamine did not demonstrate a promising efficacy in ADHD, memantine and donepezil showed effectiveness. However, future studies are needed to confirm their efficacy in ADHD since there was some inconsistency. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Synthesis of a Rivastigmine and Insulin Combinational Mucoadhesive Nanoparticle for Intranasal Delivery.
- Author
-
Jamshidnejad-Tosaramandani, Tahereh, Kashanian, Soheila, Karimi, Isaac, and Schiöth, Helgi B.
- Subjects
- *
INTRANASAL administration , *INSULIN synthesis , *NANOPARTICLES , *INSULIN , *DRUG delivery systems , *ALZHEIMER'S disease , *NASAL mucosa , *PANCREATIC beta cells , *CHITOSAN - Abstract
Efficient drug delivery remains a critical challenge for treating neurodegenerative diseases, such as Alzheimer's disease (AD). Using innovative nanomaterials, delivering current medications like acetylcholinesterase inhibitors to the brain through the intranasal route is a promising strategy for managing AD. Here, we developed a unique combinational drug delivery system based on N,N,N-trimethyl chitosan nanoparticles (NPs). These NPs encapsulate rivastigmine, the most potent acetylcholinesterase inhibitor, along with insulin, a complementary therapeutic agent. The spherical NPs exhibited a zeta potential of 17.6 mV, a size of 187.00 nm, and a polydispersity index (PDI) of 0.29. Our findings demonstrate significantly improved drug transport efficiency through sheep nasal mucosa using the NPs compared to drug solutions. The NPs exhibited transport efficiencies of 73.3% for rivastigmine and 96.9% for insulin, surpassing the efficiencies of the drug solutions, which showed transport efficiencies of 52% for rivastigmine and 21% for insulin ex vivo. These results highlight the potential of a new drug delivery system as a promising approach for enhancing nasal transport efficiency. These combinational mucoadhesive NPs offer a novel strategy for the simultaneous cerebral delivery of rivastigmine and insulin, which could prove helpful in developing effective treatments of AD and other neurodegenerative conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Rivastigmine for the management of anticholinergic delirium.
- Author
-
Chiew, Angela L., Holford, Amanda G., Chan, Betty S. H., and Isoardi, Katherine Z.
- Abstract
Anticholinergic agents are commonly taken in overdose, often causing delirium. The spectrum of anticholinergic delirium ranges from mild agitation to severe behavioural disturbance. Physostigmine is an effective treatment for anticholinergic delirium, but its availability is limited. As rivastigmine is readily available, it has been used to manage anticholinergic delirium; however, there is limited research investigating its use. This was a retrospective review of patients with anticholinergic delirium treated in two toxicology units with rivastigmine (oral capsule or transdermal patch) from January 2019 to June 2023. The primary outcome was the use of further parenteral treatment (sedation or physostigmine) for delirium post rivastigmine administration. Fifty patients were administered rivastigmine for the management of anticholinergic delirium. The median age was 36 years (interquartile range: 25–49 years) and 27 (54 per cent) were females. Features consistent with anticholinergic toxicity included tachycardia in 44 (88 per cent) and urinary retention requiring catheterisation in 40 (80 per cent). Forty-three patients (86 per cent) were treated with physostigmine before rivastigmine administration. Twenty-two were managed with transdermal rivastigmine (most commonly 9.5 mg/24 hour patch), and 28 with oral rivastigmine 6 mg. Further parenteral sedation and/or physostigmine treatment were required more often in patients given transdermal than oral rivastigmine [16/22 (73 per cent) versus 9/28 (32 per cent), P = 0.010)]. No patients had bradycardia or gastrointestinal symptoms following rivastigmine administration. One patient with a history of epilepsy had a seizure, 1.5 hours post physostigmine administration and 7 hours post transdermal rivastigmine. Rivastigmine has been increasingly used for the management of patients with anticholinergic delirium, due to the lack of availability of physostigmine. In this case series, rivastigmine transdermal patch appeared to be less effective than oral rivastigmine capsules, likely due to its slow onset of action and/or insufficient dose. Rivastigmine can be used to treat anticholinergic delirium. In our case series oral rivastigmine appeared more effective than transdermal rivastigmine. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. The effects of rivastigmine on neuropsychiatric symptoms in the early stages of Parkinson's disease: A systematic review.
- Author
-
Reilly, Siobhan, Dhaliwal, Simran, Arshad, Usman, Macerollo, Antonella, Husain, Nusrat, and Costa, Antonio Da
- Subjects
- *
APATHY , *PARKINSON'S disease , *RIVASTIGMINE , *RAPID eye movement sleep , *BEHAVIOR disorders , *MOVEMENT disorders , *SLEEP disorders - Abstract
Background and purpose: Neuropsychiatric symptoms including depression, apathy and psychosis occur frequently in patients with Parkinson's disease. A subgroup of patients develop cognitive impairment, which may increase the risk of falls due to reduced attention. The acetylcholinesterase inhibitor rivastigmine is beneficial in Parkinson's disease dementia, but whether the use of rivastigmine is effective earlier in the disease course is unclear. The aim of this systematic review was to assess the evidence for rivastigmine in the treatment of neuropsychiatric symptoms in Parkinson's disease without dementia. Methods: Embase, Medline, PsychINFO, Cochrane CENTRAL, NGLC, National Institute for Health and Care Excellence Evidence and medRxiv.org were searched for studies with terms relating to population (Parkinson's disease) and intervention (rivastigmine). Of 1922 references identified, 358 were duplications. Following title and abstract review, 1331 articles were excluded. After full‐text review, nine articles remained. Results: Outcomes were heterogenous, therefore, the results are presented in narrative form. The articles included six randomized controlled trials, two open‐label trials and one case series. Outcome measures included: time to develop psychosis; frequency of rapid eye movement sleep behaviour disorder (RBD) episodes; apathy; gait variability; falls; cognitive ability; Neuropsychiatric Inventory score; and regional spontaneous brain activity. Conclusions: There is evidence that rivastigmine is beneficial for RBD and apathy in Parkinson's disease patients without dementia. There is high level evidence that rivastigmine reduces falls, which may be due to improved attention. The impact of rivastigmine on psychotic symptoms is less clear, but is supported by current theoretical models which involve acetylcholine dysfunction in the generation of visual hallucinations in Parkinson's disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Cholinesterase inhibitors-associated torsade de pointes/QT prolongation: a real-world pharmacovigilance study.
- Author
-
Ni Zhang, Lanlan Gan, Guiyuan Xiang, Jing Xu, Tingting Jiang, Yanping Li, Yuanlin Wu, Rui Ni, and Yao Liu
- Subjects
ATORVASTATIN ,OLDER women ,CHOLINESTERASE inhibitors ,ALZHEIMER'S disease ,OLDER people ,RIVASTIGMINE - Abstract
Objective: Cholinesterase inhibitor (ChEIs) is the first-line drug for Alzheimer's disease (AD). Understanding torsade de pointes (TdP)/QT prolongation with different ChEIs is essential for its safe and rational administration. This study aimed to evaluate the correlation between different ChEIs and TdP/QT prolongation. Methods: All ChEIs related TdP/QT prolongation cases were retrieved from the FAERS database using standard MedDRA query (SMQ) from the first quarter of 2004 to the third quarter of 2022. Disproportionality and sensitivity analysis were used to determine the signal of TdP/QT prolongation related to ChEIs. Results: 557 cases of TdP/QT prolongation related to 3 ChEIs were searched by SMQ. The patients were mostly elderly people, with markedly more female than male. The signals of TdP/QT prolongation for ChEIs were detected by disproportionality analysis, and the signal of Donepezil was the strongest. The sensitivity analysis results indicate a robust and stable correlation between these signals with ChEIs. TdP/QT prolongation usually occurs within 1 month after taking ChEIs. The drug with the highest frequency of combination with donepezil and galantamine is citalopram, and the drug with the highest frequency of combination with rivastigmine is atorvastatin. Conclusion: The signals of TdP/QT prolongation related to ChEIs were strong and stable. It is necessary to be vigilant about the TdP/QT prolongation of various ChEIs, especially in elderly women, the initial stage after taking ChEIs, and when ChEIs combining with drugs that could prolong the QT interval. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Development and Characterization of Rivastigmine Hydrogen Tartrate Elementary Osmotic Tablets.
- Author
-
Naz, Ayesha, Subrahmanyam, C. V. S., and Rachamalla, Shyam Sunder
- Subjects
- *
RIVASTIGMINE , *OSMOTIC pressure , *FACTORIAL experiment designs , *WEIGHT gain , *POLYETHYLENE glycol - Abstract
Background: The present study aims to develop an Elementary Osmotic tablet (EOP) of Rivastigmine Hydrogen Tartrate (RHT). EOP consists of a core tablet suitably coated with a polymeric solution, and an orifice drilled on one side of the tablet. Materials and Methods: The influence of core variables, including sodium chloride (osmogen) concentration and Polyvinyl Pyrrolidine K30 (PVP K30) concentration, have been investigated and optimized by factorial design. The effect of membrane (coating) variables, including polyethylene glycol 400 (PEG 400) amount and percent coating weight gain have been studied. The rivastigmine release of the optimized system has been investigated in various dissolution media, at different stirring rates, at variable pH, and variable osmotic pressure. Results: It was observed that PEG 400 incorporated in the coating membrane improved drug release. The sodium chloride had a profoundly positive influence, and PVP K30 had a negative influence on the rivastigmine release. The finding reveals that the core tablet containing sodium chloride (50 mg) and PVP K30 (2.5 mg) coated with the solution containing 20% PEG 400 and 5% weight gain was optimized. Conclusion: The developed EOP provides the RHT release for up to 24 hr with improved bioavailability. The results instigated a controlled release of rivastigmine. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Rivastigmine–Bambuterol Hybrids as Selective Butyrylcholinesterase Inhibitors.
- Author
-
Wu, Jie, Tan, Zekai, Pistolozzi, Marco, and Tan, Wen
- Subjects
- *
ACETYLCHOLINESTERASE , *BUTYRYLCHOLINESTERASE , *ALZHEIMER'S disease , *BLOOD-brain barrier - Abstract
Selective butyrylcholinesterase inhibitors are considered promising drug candidates for the treatment of Alzheimer's disease. In this work, one rivastigmine–bambuterol hybrid (MTR-1) and fourteen of its analogues were synthesized, purified, and characterized. In vitro cholinesterase assays showed that all the compounds were more potent inhibitors of BChE when compared to AChE. Further investigations indicated that MTR-3 (IC50(AChE) > 100,000 nM, IC50(BChE) = 78 nM) was the best compound in the series, showing high butyrylcholinesterase selectivity and inhibition potency, the potential to permeate the blood–brain barrier, and longer-lasting BChE inhibition than bambuterol. These compounds could be used to discover novel specific BChE inhibitors for the treatment of Alzheimer's disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. In silico analysis of the use of solanine derivatives as a treatment for Alzheimer's disease
- Author
-
Baydaa Hamad Obaid Saleh, Manar Dawood Salman, Ali Dawood Salman, Saja Mohsen Alardhi, Malik M. Mohammed, István Gábor Gyurika, Phuoc-Cuong Le, and Osamah Ihsan Ali
- Subjects
In silico ,solanine derivatives ,Alzheimer's disease ,Rivastigmine ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Alzheimer's disease (AD) is a brain illness that causes cognitive impairment in the elderly, especially females, as a result of genetics, hormones, and life experiences. It becomes more severe with age and is associated with cardiovascular disease, hypertension, and diabetes. Beta-amyloid plaques and hyper phosphorylated Tau protein buildup are common clinical findings. Misfiling of amyloid precursor protein (APP) and Amyloid beta peptide (Aβ) proteins contributes to Alzheimer's disease. Enzyme Acetylcholinesterase enzyme interacts with amyloid-beta, enhancing its accumulation in insoluble plaques, leading to successful treatment for Alzheimer's disease primarily based on lowering this enzyme. Treatments include using the Rivastigmine for mild, moderate, or severe Alzheimer's disease, which inhibits acetylcholinesterase, but may cause side effects; Solanine derivatives, nightshade toxin, it is cholinesterase inhibitory, may mitigate Alzheimer's illness is progressing. In this research utilized a molecular docking program, which is a computer's computational ability to determine the optimal position for a specific compound to bind to a protein or target, forming a target-ligand complex and displaying biological activity and aiding in the development of effective anti-AD treatments and understanding AD pathological mechanisms. The study examined complexes of 3LII (Acetylcholinesterase receptor) in the A and B chain with Solanine and Rivastigmine derivatives, using an in-silico approach. PyRx default sorter was used to improve docking accuracy. Four compounds were selected based on their higher binding affinities in chain A and B. The results showed that Solanine derivatives (alpha-Solanine, Beta1-Solanine and Beta2-Solanine) have higher binding strength (−9.0,-9.3 and −8.6) than Rivastigmine (−7.2) in chain A, and also the binding strength was high for the Solanine derivatives (alpha-Solanine, Beta1-Solanine, and Beta2-Solanine) (−9.0,-8.8 and −8.9) is higher than Rivastigmine (−6.0) in the chain B. Solanine derivatives showed higher binding strength with acetylcholinesterase, potentially for to reduce the progression of the disease.
- Published
- 2024
- Full Text
- View/download PDF
38. Hydromethylthionine rescues synaptic SNARE proteins in a mouse model of tauopathies: Interference by cholinesterase inhibitors
- Author
-
Karima Schwab, Dilyara Lauer, Mandy Magbagbeolu, Franz Theuring, Anna Gasiorowska, Maciej Zadrozny, Charles R. Harrington, Claude M. Wischik, Grażyna Niewiadomska, and Gernot Riedel
- Subjects
Tau protein ,Alzheimer’s disease ,HMTM ,Cholinesterase inhibitors ,Rivastigmine ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
In clinical trials for Alzheimer’s disease (AD), hydromethylthionine mesylate (HMTM) showed reduced efficacy when administered as an add-on to symptomatic treatments, while it produced a significant improvement of cognitive function when taken as monotherapy. Interference of cholinesterase inhibition with HMTM was observed also in a tau transgenic mouse model, where rivastigmine reduced the pharmacological activity of HMTM at multiple brain levels including hippocampal acetylcholine release, synaptosomal glutamate release and mitochondrial activity. Here, we examined the effect of HMTM, given alone or in combination with the acetylcholinesterase inhibitor, rivastigmine, at the level of expression of selected pre-synaptic proteins (syntaxin-1; SNAP-25, VAMP-2, synaptophysin-1, synapsin-1, α-synuclein) in brain tissue harvested from tau-transgenic Line 1 (L1) and wild-type mice using immunohistochemistry. L1 mice overexpress the tau-core unit that induces tau aggregation and results in an AD-like phenotype. Synaptic proteins were lower in hippocampus and cortex but greater in basal forebrain regions in L1 compared to wild-type mice. HMTM partially normalised the expression pattern of several of these proteins in basal forebrain. This effect was diminished when HMTM was administered in combination with rivastigmine, where mean protein expression seemed supressed. This was further confirmed by group-based correlation network analyses where important levels of co-expression correlations in basal forebrain regions were lost in L1 mice and partially re-established when HMTM was given alone but not in combination with rivastigmine. These data indicate a reduction in pharmacological activity of HMTM when given as an add-on therapy, a result that is consistent with the responses observed in the clinic. Attenuation of the therapeutic effects of HMTM by cholinergic treatments may have important implications for other potential AD therapies.
- Published
- 2024
- Full Text
- View/download PDF
39. Treatment of Anticholinergic Delirium with Oral Rivastigmine: A Case Report.
- Author
-
Karousatos, Christopher and Murphy, Lauren
- Subjects
- *
RIVASTIGMINE , *DELIRIUM , *PUPILLARY reflex , *EMERGENCY physicians , *ACETYLCHOLINESTERASE inhibitors , *URINARY urge incontinence - Abstract
Anticholinergic toxicity is commonly encountered in the emergency department. However, the availability of physostigmine, a central acetylcholinesterase inhibitor used to reverse anticholinergic delirium, has been significantly limited due to national drug shortages in the United States. Several articles have explored the viability of rivastigmine as an alternative treatment in these patients. A 33-year-old man presented to the emergency department after a suspected suicide attempt. The patient was found with an empty bottle of diphenhydramine at the scene. On arrival, he was tachycardic and delirious, with dilated and nonreactive pupils and dry skin. As the clinical picture was highly suggestive of anticholinergic toxicity, the patient was treated with oral rivastigmine at a starting dose of 4.5 mg to reverse his anticholinergic delirium. Although a repeat dose was required, his delirium resolved without recurrence. Why Should an Emergency Physician Be Aware of This? Oral rivastigmine has been applied successfully here and in other case reports to reverse anticholinergic delirium with the benefit of prolonged agitation control. Emergency physicians may consider this medication in consultation with a specialist, with initial doses starting at 4.5–6 mg, if encountering anticholinergic delirium when physostigmine is not available. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Formulation and optimization of rivastigmine-loaded PLGA and chitosan nanoparticles for transdermal delivery
- Author
-
Priya, Sneh, Poornima, and Lobo, Cynthia Lizzie
- Published
- 2023
- Full Text
- View/download PDF
41. Carbamate as a potential anti‐Alzheimer's pharmacophore: A review.
- Author
-
Singh, Yash Pal, Kumar, Navneet, Chauhan, Brijesh Singh, and Garg, Prabha
- Subjects
- *
ALZHEIMER'S disease , *AMYLOID plaque , *ACETYLCHOLINESTERASE inhibitors , *METHYL aspartate receptors , *RIVASTIGMINE , *MUSCARINIC receptors , *PHARMACOPHORE - Abstract
Alzheimer's disease (AD) is a progressive age‐related neurodegenerative brain disorder, which leads to loss of memory and other cognitive dysfunction. The underlying mechanisms of AD pathogenesis are very complex and still not fully explored. Cholinergic neuronal loss, accumulation of amyloid plaque, metal ions dyshomeostasis, tau hyperphosphorylation, oxidative stress, neuroinflammation, and mitochondrial dysfunction are major hallmarks of AD. The current treatment options for AD are acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine) and NMDA receptor antagonists (memantine). These FDA‐approved drugs mainly provide symptomatic relief without addressing the pathological aspects of disease progression. So, there is an urgent need for novel drug development that not only addresses the basic mechanisms of the disease but also shows the neuroprotective property. Various research groups across the globe are working on the development of multifunctional agents for AD amelioration using different core scaffolds for their design, and carbamate is among them. Rivastigmine was the first carbamate drug investigated for AD management. The carbamate fragment, a core scaffold of rivastigmine, act as a potential inhibitor of acetylcholinesterase. In this review, we summarize the last 10 years of research conducted on the modification of carbamate with different substituents which primarily target ChE inhibition, reduce oxidative stress, and modulate Aβ aggregation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
42. Intramuscularly Administered PLGA Microparticles for Sustained Release of Rivastigmine: In Vitro, In Vivo and Histological Evaluation.
- Author
-
Avendaño-Godoy, Javier, Miranda, Arnoldo, Mennickent, Sigrid, and Gómez-Gaete, Carolina
- Subjects
- *
RIVASTIGMINE , *CONTROLLED release drugs , *ACETYLCHOLINESTERASE , *ALZHEIMER'S disease , *PHARMACOKINETICS , *POLYLACTIC acid - Abstract
Rivastigmine is an acetylcholinesterase (AchE) and butyrylcholinesterase (BchE) inhibitor drug approved by the US Food and Drug Administration (FDA) for the treatment of mild to moderate dementia of Alzheimer's type. However, its first-pass metabolism and gastrointestinal side effects negatively affect the tolerability and efficacy of oral therapy. These adverse effects could be avoided with the use of a sustained -release formulation as an intramuscular (IM) administration system. The objective of this work was to develop polylactic co-glycolic acid (PLGA) microparticles for the sustained release of rivastigmine and to evaluate its stability during storage, tissue tolerance, in vitro release, and in vivo pharmacokinetics after its IM administration. The microparticles were made by the solvent evaporation emulsion method. A series of formulation parameters (the type of polymer used, the amount of polymer used, the initial amount of rivastigmine, and the volume of PVA 0.1% w/v) were studied to achieve an encapsulation efficiency (EE) and a rivastigmine load of 54.8 ± 0.9% and 3.3 ± 0.1%, respectively. The microparticles, whose size was 56.1 ± 2.8 μm, had a spherical shape and a smooth surface. FT-IR analysis showed that there is no chemical interaction between rivastigmine and the polymer. PLGA microparticles maintain rivastigmine retained and stable under normal (5 ± 3 °C) and accelerated storage (25 ± 2 °C and 60 ± 5 % RH) conditions for at least 6 months. The microparticles behaved as a sustained release system both in vitro and in vivo compared to non-encapsulated rivastigmine. The IM administration of the formulation in rats did not produce significant tissue damage. However, it is necessary to reproduce the experiments with multiple doses to rule out a negative effect in terms of tolerability in chronic treatment. To the best of our knowledge, this study is the only one that has obtained the sustained release of rivastigmine from PLGA microparticles after IM administration in an in vivo model. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
43. Oral Dissolving Film of Rivastigmine: Optimization Using Factorial Design.
- Author
-
Farghaly, Dalia A., Afifi, Samar A., Aboelwafa, Ahmed A., and Mohamed, Magdy I.
- Abstract
Purpose: Due to impairments in memory and judgment, it is difficult for dementia patients to understand why they need medicine. Moreover, they often have swallowing difficulties. In this investigation, an oral dissolving film of rivastigmine tartrate (RT-ODF) was developed, offering a unique and convenient formulation for dementia patients. Methods: RT-ODF was developed using a solvent-casting technique. Sodium alginate and sodium carboxymethyl cellulose were used as film-forming polymers, and glycerol was used as a plasticizer. A full factorial design (3
2 ) was employed to estimate the impact of two factors at three levels: polymer concentration (1, 1.5, and 2% w/v) and plasticizer concentration (30, 40, and 50% w/v) on the responses, i.e., the tensile strength (TS), the disintegration time (DT), and the quantity of drug released (Q10 min). Results: The optimized formula (A1) that had the highest desirability value (0.923) exhibited the lowest tensile strength (3.67 ± 0.72 MPa), the shortest disintegration time (20 ± 2.0 s), and the highest percentage of drug released after 10 min (97.12 ± 2.01%). It was composed of 1% w/v sodium alginate (ALG-Na) and plasticized with 30% w/v glycerol. The pharmacokinetic study revealed that the RT-ODFs enhanced the drug's bioavailability by 1.91-fold relative to the reference product (Exelon® capsule). Conclusion: Oral dissolving films of rivastigmine tartrate could be a promising approach to promote drug bioavailability and convenience for geriatric patients. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
44. Compliance with National and International Guidelines in the Treatment of Nonmotor Symptoms in Late-Stage Parkinson's Disease.
- Author
-
Rosqvist, Kristina and Odin, Per
- Subjects
- *
HALLUCINATIONS , *ANTIDEPRESSANTS , *SYNCOPE , *BOTULINUM toxin , *LAXATIVES , *DELUSIONS , *RIVASTIGMINE , *DIZZINESS , *CONSTIPATION , *ORTHOSTATIC hypotension , *DROOLING , *MEDICAL protocols , *PARKINSON'S disease , *QUALITY of life , *RESEARCH funding , *MENTAL depression , *DEMENTIA , *DONEPEZIL , *INSOMNIA , *ANTIPSYCHOTIC agents , *DROWSINESS , *SYMPTOMS - Abstract
Background. National as well as international Parkinson's disease (PD) treatment guidelines are available to guide clinicians. Previous research has shown that nonmotor symptoms (NMS) are pronounced in late-stage PD and has suggested that current treatment is insufficient and could be improved. Objectives. The aim of this study was to investigate to which degree the national and international treatment guidelines are followed in the treatment of NMS in late-stage PD. Methods. This Swedish cohort was part of the Care of Late-Stage Parkinsonism (CLaSP) study. Late-stage PD was defined as Hoehn and Yahr stages IV-V in "on" and/or ≤50% on the Schwab and England Activities of Daily Living (ADL) scale. NMS were assessed with the NMS scale (NMSS), cognition with the Mini-Mental State Examination (MMSE), and depressive symptoms with the Geriatric Depression Scale (GDS-30). Symptomatic individuals were defined as ≥ 6 on an item of the NMSS; for dementia, a cutoff of ≤18 on the MMSE; for depression, a cutoff of ≥10 on the GDS. Results. All 107 participants exhibited NMS to various degrees and severities; the median NMSS score was 91. Among symptomatic individuals, for depressive symptoms, 37/63 (59%) were treated with antidepressants; for hallucinations and delusions, 9/18 (50%) and 5/13 (38%) were treated with antipsychotics; and for dementia, 9/27 (33%) were treated with rivastigmine and 1 (4%) was treated with donepezil. For orthostatic hypotension, 11/19 (58%) with lightheadedness and 7/8 (88%) with fainting were treated with antihypotensives; for sialorrhea, 2/42 (5%) were treated with botulinum toxin; and for constipation, 19/35 (54%) were treated with laxatives. For insomnia, 4/16 (25%) were treated with hypnotics, and for daytime sleepiness, 1/29 (3%) was treated with psychostimulants. Conclusions. The present analyses suggest a need for clinicians to further screen for and treat NMS. Optimizing treatment of NMS according to the national and international treatment guidelines may improve symptomatology and enhance quality of life in late-stage PD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
45. Prescription of transdermal patches in Colombia: A real-world evidence study.
- Author
-
Valladales-Restrepo, Luis Fernando, Gaviria-Mendoza, Andrés, Londoño-Serna, María José, Ospina-Cano, Juan Alberto, Giraldo-Giraldo, Claudia, Machado-Duque, Manuel Enrique, and Machado-Alba, Jorge Enrique
- Subjects
- *
STATISTICS , *LIDOCAINE , *PROFESSIONS , *RIVASTIGMINE , *ANTILIPEMIC agents , *CROSS-sectional method , *BUPRENORPHINE , *ESTRADIOL , *CHRONIC diseases , *AGE distribution , *TRANSDERMAL medication , *RETROSPECTIVE studies , *MEDICATION errors , *FENTANYL , *MANN Whitney U Test , *FISHER exact test , *SEX distribution , *DEMENTIA patients , *BENIGN prostatic hyperplasia , *INAPPROPRIATE prescribing (Medicine) , *DRUG prescribing , *LEGAL compliance , *DESCRIPTIVE statistics , *CHI-squared test , *PHYSICIAN practice patterns , *STATISTICAL sampling - Abstract
BACKGROUND: Transdermal drug delivery has contributed positively to medical practice. However, prescriptions that do not meet minimum quality criteria and medication errors are common. OBJECTIVE: The objective was to determine how transdermal patches are being prescribed to a group of patients in Colombia, the compliance with established requirements of such prescriptions and the comparisons between correct and incorrect prescriptions. METHODS: This was a cross-sectional study of prescriptions for transdermal patches using data from a population-based drug dispensing database between December 1 and 31, 2019. Medical prescriptions were randomly reviewed, establishing whether the drugs were appropriately prescribed by the manufacturer's indications or national regulations. Descriptive and bivariate analysis was performed. RESULTS: A total of 415 prescriptions were reviewed; the prescription was provided to 412 patients with a median age of 76.9 years, and 63.3% were women. Rivastigmine was the most prescribed transdermal patch (57.8%). 66.3% of all prescriptions did not meet the minimum appropriate prescribing standards, especially those for rivastigmine (97.1%). The 7.0% of all prescriptions had posology errors, especially prescriptions for buprenorphine (43.8%). Older patients (84.4% vs 52.5%), from the Pacific region (34.4% vs 23.7%), with manual formulations (22.1% vs 0.8%), dementia (49.0% vs 6.8%), and in management with lipid-lowering drugs (41.8% vs 30.5%), presented incorrect transdermal patch formulations more frequently (p < 0.05). CONCLUSION: The high proportion of inappropriately prescribed transdermal patches should draw the attention of those responsible for health care to improve the training of physicians and create prescription quality verification systems. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
46. Rivastigmine als ondersteuning bij het dilemma van de behandeling van hallucinaties optredend bij ziekte van Parkinson
- Author
-
jmp Rovers, plj Dautzenberg, and jp ter bruggen
- Subjects
rivastigmine ,Parkinson ,hallucinaties ,Medicine - Abstract
Casusbespreking van drie patie¨nten opgenomen in verband met hallucinaties bij de ziekte van Parkinson zonder dementie waarbij naast aanpassing van de anti-parkinson medicatie tevens wordt gestart met rivastigmine waardoor hallucinaties verdwenen en niet meer recidiveerden. Een 79-jarige man kreeg in verband met onrust tevens kortdurend quetiapine, terwijl de anti-parkinson medicatie probleemloos kon worden opgehoogd waardoor mobiliteit verbeterde; een 84-jarige vrouw gaf milde bijwerkingen aan van de rivastigmine, zonder noodzaak tot staken van rivastigmine, terwijl de mobiliteit goed bleek te zijn; een 72-jarige vrouw vertoonde bij opname milde geheugenproblemen die verbeterden, waarbij ook de mobiliteit verbeterde na verdere ophoging van de anti-parkinson medicatie. De behandeling met rivastigmine kan helpen in het therapeutisch dilemma (starten anti-psychoticum of verlagen anti-parkinson medicatie). Naast het aanpassen van de anti-parkinson medicatie en soms het tijdelijk behandelen met een anti-psychoticum lijkt rivastigmine bij hallucinaties bij ziekte van Parkinson in relatief korte tijd verbetering te geven zonder veel bijwerkingen. Deze verbetering bestaat uit verbleken hallucinaties en verbeteren van de mobiliteit, doordat indien nodig anti-parkinson medicatie kan worden opgehoogd. De vele vragen die echter resteren maken prospectief gerandomiseerde trials naar deze indicatie noodzakelijk.
- Published
- 2024
- Full Text
- View/download PDF
47. Medicamenteuze behandeling van de ziekte van Alzheimer. De klinische praktijk in Nederland
- Author
-
CJM Scho¨lzel-Dorenbos
- Subjects
Dementie ,Ziekte van ALzheimer ,Farmacotherapie ,Rivastigmine ,Galantamine ,Memantine ,Medicine - Abstract
Dementie treft op dit moment in Nederland 195.000 patie¨nten van 65 jaar en ouder. De meest frequente etiologie van dementie is de ziekte van Alzheimer (ZvA). De acetylcholinesteraseremmers rivastigmine en galantamine en de NMDA (N-methyl-D-aspartate) antagonist memantine zijn in ons land geregistreerd voor behandeling van de ZvA, respectievelijk voor de milde tot matig ernstige en matig ernstige tot ernstig vorm. Alle middelen worden op dit moment onder bepaalde voorwaarden vergoed. Rivastigmine en galantamine hebben een gering effect dat goed is onderzocht. Memantine heeft mogelijk bij een klein deel van de patie¨nten een zeer bescheiden effect, de respons op drie domeinen is na een behandeling van zes maanden nog onvoldoende aangetoond. Wij beschrijven een aantal patie¨nten die worden behandeld met deze medicijnen, om de dagelijkse praktijk toe te lichten en bespreken het voor en tegen van medicamenteuze behandeling bij de ziekte van Alzheimer. Voor optimale behandeling van patie¨nten en de juiste advisering en begeleiding van hun verzorgers zijn kennis van farmacotherapie en andere vormen van behandeling en begeleiding en van de diagnostiek van dementie een noodzakelijke voorwaarde.
- Published
- 2024
- Full Text
- View/download PDF
48. Case 11. Two Faces of the Medallion
- Author
-
Tascilar, Nida F., Schenck, Carlos H., and Rodriguez, Alcibiades J., editor
- Published
- 2023
- Full Text
- View/download PDF
49. GUATEMALAN INSTITUTE OF SOCIAL SECURITY -IGSS- invites tenders for Code 10566 -Rivastigmine Capsule 4.5 Mg - Fyb Order 1967/2024
- Subjects
Rivastigmine ,News, opinion and commentary - Abstract
GUATEMALAN INSTITUTE OF SOCIAL SECURITY -IGSS-, Guatemala has invited tenders for Code 10566 -Rivastigmine Capsule 4.5 Mg - Fyb Order 1967/2024. Tender Notice No: 23871687 Deadline: August 26, 2024 Copyright [...]
- Published
- 2024
50. MINISTRY OF HEALTH, DEPARTMENT OF PHARMACY invites tenders for Pharmacy Department, Hkl - Supply and Delivery Rivastigmine 13.3Mg/24Hr Transdermal Patch
- Subjects
Pharmacy ,Transdermal medication ,Rivastigmine ,News, opinion and commentary - Abstract
MINISTRY OF HEALTH, DEPARTMENT OF PHARMACY, Malaysia has invited tenders for Pharmacy Department, Hkl - Supply and Delivery Rivastigmine 13.3Mg/24Hr Transdermal Patch. Tender Notice No: QT240000000021692 Deadline: August 8, 2024 [...]
- Published
- 2024
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.